Is ANAVEX LIFE SCIENCES CORP. (AVXL) Halal?
Shariah Screening — 5 Standards
Based on financial data from September 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 23.8% / 30% | 0.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 23.8% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 98.8% / 33% | 0.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 23.8% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 98.8% / 33% | 0.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -33.6% | |
| Return on Assets (ROA) | -21.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$39M |
| Free Cash Flow | -$39M |
| Current Ratio | 20.9 |
| Total Assets | $104M |
Price & Trading
| Last Close | $2.88 |
| 50-Day MA | $4.41 |
| 200-Day MA | $7.08 |
| Avg Volume | 1.4M |
| Beta | 1.0 |
|
52-Week Range
$2.61
| |
About ANAVEX LIFE SCIENCES CORP. (AVXL)
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ANAVEX LIFE SCIENCES CORP. (AVXL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ANAVEX LIFE SCIENCES CORP. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ANAVEX LIFE SCIENCES CORP.'s debt ratio?
ANAVEX LIFE SCIENCES CORP.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are ANAVEX LIFE SCIENCES CORP.'s key financial metrics?
ANAVEX LIFE SCIENCES CORP. has a market capitalization of $261M. Return on equity stands at -33.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.